ENTHERA-PHARMACEUTICALS
28.7.2020 10:02:05 CEST | Business Wire | Press release
Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the completion of a €28 million Series A financing round.
The Series A was co-led by seed investor Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, and incoming investor AbbVie, with further investment from the JDRF T1D Fund (the venture capital fund of JDRF) and several Italian investors including a group coordinated by Banor SIM, a group coordinated by Banca Profilo through Arepo Fiduciaria and Indaco Venture Partners SGR. The €28 million raised is the largest VC-backed Series A funding round for an Italian biotechnology company to date.
The Series A marks AbbVie’s first venture investment into an Italian company. Enthera was also the first European investment of the JDRF T1D fund, who previously invested in the Company during its €4 million seed extension funding round in 2018.
The proceeds from the Series A financing will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001, Enthera’s lead candidate. Ent001 is the only drug in development with the potential to restore the pancreatic beta cell compartment in type 1 diabetes as well as the original intestine structure in inflammatory bowel disease, in order to re-establish organ function. The funds will also be used to further develop Enthera’s pipeline.
Commenting on the successful Series A financing, Giovanni Amabile, CEO of Enthera, said: “Having renowned investors Sofinnova Partners, AbbVie and JDRF T1D Fund choosing to support us on our journey is great validation of our company strategy and scientific method, and gives credit to the innovative science that is currently underway in Italy.
“We have a revolutionary approach that offers a new perspective for intractable diseases such as type 1 diabetes and inflammatory bowel disease, and the funds raised will enable us to accelerate our lead program Ent001 to clinical proof-of-concept. Through this and the development of our wider pipeline, we have the opportunity to bring real hope to patients in need and to provide effective and safe treatments.”
Graziano Seghezzi, Managing Partner of Sofinnova Partners, who co-seeded the company, stated:
“Enthera’s Series A financing is a fantastic milestone enabled by the leadership of Giovanni who, since his arrival in the company, has expanded its activities into novel therapeutic areas. This is also an opportunity for us to applaud BiovelocITA’s role in transforming the breakthrough science originating from Paolo Fiorina and his team into a full-fledged enterprise. Enthera is a salient example of what can be achieved when the critical components of a biotech ecosystem are brought together to accelerate innovation in Italy: World-class science, experienced management, and dedicated financial capital.”
Margarita Chavez, Managing Director of AbbVie Ventures and new addition to the Enthera Board of Directors, added: “AbbVie Ventures’ investment in Enthera’s Series A demonstrates our confidence in the team and their unique approach to treating underserved autoimmune disorders. I look forward to working with Giovanni and rest of the team as we drive the Company and its innovation forward.”
Enthera was formed in 2016 on the basis of research by scientific founders Prof. Paolo Fiorina and Dr. Francesca D’Addio. The Company is the first spin-off of the Italian biotech accelerator BiovelocITA, founded by Sofinnova Partners, Silvano Spinelli and Gabriella Camboni, which provided the initial seed fund. A seed extension was financed in 2018 by Sofinnova Partners, JDRF T1D fund and the other existing investors.
ENDS
Notes to Editors
About Enthera
Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Company’s primary target indications are type 1 diabetes (T1D) and inflammatory bowel disease (IBD).
Enthera's pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in beta cell and stem cell apoptosis in pancreas and gut, respectively.
The Company is building a pipeline of inhibitory monoclonal antibodies (mAbs) and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, in order to re-establish organ function.
Enthera is a private company headquartered in Milan, Italy and founded in 2016 by Prof Paolo Fiorina and Dr Francesca D’Addio at BiovelocITA, an Italian biotech accelerator. The Company is backed by Sofinnova Partners and JDRF T1D fund. Enthera’s discovery engine and assets are protected by a broad portfolio of patents.
For more information, visit https://www.entherapharmaceuticals.com/
Connect with us on LinkedIn .
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
For more information, please visit: www.sofinnovapartners.com
About AbbVie Ventures
AbbVie Ventures is the corporate venture capital group of AbbVie. We are a strategic investor, investing exclusively in novel, potentially transformational science aligned with AbbVie's core R&D interests. We measure success primarily by the extent to which our investments foster innovation with potential to transform the lives of patients that AbbVie serves. AbbVie Ventures enables its portfolio companies with both funding as well as access to AbbVie's internal network of experts across all phases of drug development, from drug discovery through commercialization.
For more information, please visit www.abbvie.com/ventures
For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on Twitter, Facebook , Instagram , YouTube and LinkedIn .
About the JDRF T1D Fund
The JDRF T1D Fund is a venture philanthropy fund accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D) through catalytic equity investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance therapeutics, devices, diagnostics and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund reinvests any realized gains into new investments to further its mission.
BiovelocITA
BiovelocITA S.r.l. is the first Italian accelerator dedicated to biotech. It was founded by Silvano Spinelli, Gabriella Camboni and Sofinnova Partners. Thanks to BiovelocITA, entrepreneurs, scientists and investors can work together to accelerate biotech projects with an international scope and reach the “proof of concept” that precedes the clinical phase. Set up to offer innovative solutions to the medical community and to patients, BiovelocITA supports the creation and development of innovative biotech companies in all therapeutic areas.
For more information, see: http://www.biovelocita.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005076/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon Team Awarded ARPA-H Contract to Transform Care During Labor and Childbirth24.6.2026 13:05:00 CEST | Press release
New wearable monitoring system will improve clinical assessment of fetal health Carnegie Mellon University is leading a multi-university team that has secured an award of up to $39.3 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop a wearable monitoring system to better identify fetal distress and its cause, enabling a safer labor and delivery experience for mothers and babies. The system, called OMEGA, or Optical, Mechanical, and Electrical Global Assessment of fetal hypoxia, aims to replace 50-year old, indirect, unreliable fetal heart rate monitoring technology with a unified, real-time assessment of fetal oxygen delivery and adaptive capacity. The project is under ARPA-H’s Making Obstetric Care Smart program, which is led by ARPA-H Program Manager Kate Arnold, M.D., MBA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624524685/en/ Carnegie Mellon University is leading a multi-universit
€243B Tech Spend Ahead, but Only 1 in 4 Firms Achieves Scale: WBAM Research Reveals Structural Paradox24.6.2026 12:28:00 CEST | Press release
Research report by Monitor Deloitte and Objectway investigates how and why as-a-service models are gaining ground, and what separates successful execution from failed implementation.Key takeaways Firms are layering resources onto legacy, widening the gap between investment intensity and operational scalability Technology investment alone is insufficient. The real differentiator lies in how Tech&Ops capabilities are sourced, orchestrated, and delivered As-a-service adoption is set to triple in the next 2–3 years, emerging as a key lever to unlock scale According to research conducted by Monitor Deloitte, a consultancy firm, and Objectway, a growth partner for the financial services industry, wealth, banking and asset management (WBAM) firms are investing at record levels, with Technology & Operations spending reaching €173 billion globally and set to hit €243 billion by 2029. However, yet only around one in four firms has achieved true front-to-back scalability, growing their business w
PUMA Dominates HYROX World Championships From Elite Athlete Performances to Community Initiatives24.6.2026 12:15:00 CEST | Press release
Global sports brand PUMA continued its HYROX dominance at the 2026 HYROX World Championships with a host of standout elite athlete performances and iconic community moments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624897869/en/ Global sports brand PUMA continued its HYROX dominance at the 2026 HYROX World Championships with a host of standout elite athlete performances and iconic community moments, including Jake Williamson (left) and Hunter McIntyre in the Men’s Elite15 Doubles. Leading the charge was Jess Pettrow, who won the Mixed Relay with Australia for the second year in a row, with the team defending their title with an epic time of 50:19. Pettrow’s golden moment followed a fourth place finish with partner Joanna Wietrzyk in the Women’s Elite 15 Doubles, making it a highly successful weekend for the PUMA athlete. In addition to her strong showing in the Women’s Elite Doubles, Australian athlete Wietrzyk also
Rockstar Games Announces Pre-Orders for Grand Theft Auto VI24.6.2026 12:15:00 CEST | Press release
Starting at Midnight Local Time on June 25, 2026 Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is excited to announce that pre-orders for Grand Theft Auto VI will begin on June 25, 2026, at midnight local time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624539426/en/ Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is excited to announce that pre-orders for Grand Theft Auto VI will begin on June 25, 2026, at midnight local time. Launching November 19, 2026, for the PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems for $79.99, Grand Theft Auto VI features a single-player experience set in the biggest, most immersive evolution of the series yet. Launching November 19, 2026, for the PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems for $79.9
Advanced Sterilization Products (ASP) Acquires a Majority Stake in UV Smart24.6.2026 12:00:00 CEST | Press release
Advanced Sterilization Products (ASP), part of the Infection Prevention group of companies within Fortive (NYSE: FTV), announced today it has acquired a majority share of UV Smart, a leader in High Level Disinfection technology in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624367451/en/ UV Smart is renowned for its UV-C High Level Disinfection (HLD) technology that enables faster, safer and lower-cost HLD for specialty scopes. “UV Smart’s dedicated customer relationships and highly skilled team are key strengths that align perfectly with ASP’s long-term growth strategy of infection prevention,” shared Daan Hoek, co-founder of UV Smart. He continued, “Where current cleaning & disinfection processes of TEE probes can often take hours, UV Smart’s premier product, the D60, achieves high-level disinfection using UV-C light in just minutes. For healthcare providers, the D60 represents a significant improvement in ef
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom